Goldman Sachs Amends Rigel Pharma Stake on Dec 29, 2023
Ticker: RIGL · Form: SC 13G/A · Filed: Feb 5, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | SC 13G/A |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Goldman Sachs updated its Rigel Pharma holdings, watch for potential stock movement.**
AI Summary
Goldman Sachs Group Inc. filed an amended SC 13G/A on February 5, 2024, indicating a change in their beneficial ownership of Rigel Pharmaceuticals Inc. common stock as of December 29, 2023. This filing, an amendment to a previous disclosure, signals that Goldman Sachs continues to hold a significant, though potentially altered, stake in Rigel. For investors, this matters because large institutional holdings can influence stock stability and signal confidence (or lack thereof) in the company's future prospects.
Why It Matters
This filing shows that a major financial institution, Goldman Sachs, has adjusted its position in Rigel Pharmaceuticals, which can impact investor sentiment and the stock's trading dynamics.
Risk Assessment
Risk Level: low — This is a routine amendment filing by a large institutional investor, not indicating any immediate high-risk event for the company.
Analyst Insight
Investors should monitor subsequent filings from Goldman Sachs to understand the exact change in their beneficial ownership and assess if it signals a long-term shift in their investment thesis for Rigel Pharmaceuticals.
Key Players & Entities
- Goldman Sachs Group Inc. (company) — the entity filing the SC 13G/A amendment
- Rigel Pharmaceuticals Inc. (company) — the subject company whose stock is being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- February 5, 2024 (date) — the date the SC 13G/A was filed
- $.001 per share (dollar_amount) — the par value of Rigel Pharmaceuticals Inc. common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and '(Amendment No. 1)*' in the filing.
Who is the subject company of this filing?
The subject company is RIGEL PHARMACEUTICALS INC, with a Central Index Key (CIK) of 0001034842, as stated under 'SUBJECT COMPANY: COMPANY DATA'.
Who filed this SC 13G/A?
The filing was made by GOLDMAN SACHS GROUP INC, with a Central Index Key (CIK) of 0000886982, as stated under 'FILED BY: COMPANY DATA'.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 29, 2023, as explicitly stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' next to '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 5, 2024 regarding RIGEL PHARMACEUTICALS INC (RIGL).